Ask Mallard
Study design

Continual reassessment method

4 min read

The continual reassessment method updates a dose-toxicity model as outcomes arrive and selects a dose near a stated target.

NHMRC EVIDENCE LEVEL · 2009Outside the NHMRC hierarchy
Why this level?not one of the five research areas this hierarchy covers. NHMRC 2009 source

Dose selection is a feasibility and safety question, not one of the five research areas this hierarchy covers. It does not establish comparative treatment benefit.

Fit

When to use it, and when not to

Use it when

  • You need to select a dose for later study under a prespecified safety plan.
  • The toxicity outcome and its observation window can guide the next allocation.

Not when

Before you start

What you need

Decide these first
  1. Toxicity definition and targetDefine a dose-limiting toxicity and the full assessment window before recruitment.
  2. Dose levels and safety limitsFix the starting dose, allowed moves, stopping rules and independent safety oversight.
  3. Simulated trial scenariosVary toxicity curves, accrual and delayed harm. Check selection accuracy and exposure to unsafe doses.
It rests on these
  1. Pending toxicity is not absence of toxicity.How to check: Wait for the required window or use a validated extension designed for partial follow-up.
  2. The dose ordering and safety target fit the treatment.How to check: Toxicity-focused dose selection may not identify the best benefit-risk balance or biological dose.

Plain language

How it works

Set candidate doses, a target toxicity probability and a starting model before recruitment. The model links dose to toxicity and learns from observed outcomes. Select the next dose using the updated model and prespecified safety constraints. Limit jumps and define overdose stopping rules. The original method needs completed toxicity outcomes; a time-to-event extension handles partial follow-up under added assumptions.

Check the model through simulation

Vary the starting dose-toxicity guesses and true toxicity curves. Examine selection accuracy, stopping and exposure to unsafe doses. A fitted model does not guarantee safe decisions when its assumptions fit poorly.

The structure of the approach
Prespecified safety rules govern each level decision. Pending follow-up is not absence of toxicity. The complete design needs simulation under plausible scenarios. Selecting or expanding a level does not confirm efficacy.Prespecified safety rules govern each level decisionDefine target and safetyrulesObserve outcomes andpending follow-upApply the chosen designand safety constraintsEscalate only whenpermittedRetain or reduce levelStop when requiredPending follow-up is not absence of toxicity. The complete design needs simulation under plausiblescenarios. Selecting or expanding a level does not confirm efficacy.
Conceptual diagram. It shows the structure of the idea, not data from any study.

Worked example

A worked example

Invented for illustration
Setting
An early-phase trial follows a prespecified toxicity window.
Question
What do the observed counts imply under the stated design?
Approach
The target is 25 in 100. One of four patients has a dose-limiting toxicity; update the prespecified model with all outcomes.
Result
One of four patients has a toxicity: 25 in 100.
What it means
The observed share equals the target, but does not choose the next dose alone. The model and safety rules govern that decision.

In practice

Recent studies PubMed search · not vetted

Searching PubMed…

Watch out

Common mistakes

The one to remember

The next dose depends on the full model and safety constraints, not the last cohort alone. Pending outcomes require a method that accounts for delayed toxicity.

  • Equating dose selection with proof of efficacy.Instead: Selection is uncertain. Confirm benefit in a suitable later trial.
  • Changing allocation rules after a worrying result.Instead: Apply the prespecified safety and stopping rules with the safety team.

Inside Mallard

How Mallard uses this

Plans do not link to this design yet. Mallard has no sample-size form for the continual reassessment method. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.

No Mallard code example points to this page.
Atlas node design.continual_reassessment, the id a plan cue records.

How to report it

Use CONSORT-DEFINE to report the dose-selection goal, toxicity window, allocation, safety and stopping rules, deviations and participant flow. Separate observed toxicity from model estimates. State the final dose recommendation and its uncertainty. A reporting guideline is not a design manual: use it to make the study transparent, not as a substitute for careful design. Check the target journal's own requirements as well, which this page cannot know.

Related Learn pages

Related designs and methods

Evidence

Sources & further reading

  1. Continual reassessment method: a practical design for phase 1 clinical trials in cancer (opens in a new tab) · Biometrics
  2. Sequential designs for phase I clinical trials with late-onset toxicities (opens in a new tab) · Biometrics · doi 10.1111/j.0006-341x.2000.01177.x
  3. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387
Prepared with AI assistance. PubMed records checked on 2026-11-07 UTC for title, authors, year and available DOI. Record verified, confirm it supports this use. No independent professional or methodological approval is claimed.
Last source review: 2026-11-07
AI-generated educational content
Mallard uses reputable methodological and reporting sources, but this material may contain errors or omit important context. Verify important methodological decisions with the cited sources and, when appropriate, a qualified research methodologist or statistician.